Borderline personality disorder: A review of treatment approaches

Minerva Psichiatrica

Volumn 50, Issue 4, 2009, Pages 309-318

  Schulz, S C ^a   Moen, R ^a   Miller, M ^a   Long, B ^a   Romine, A ^a   Nelson, K ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Behavior therapy; Borderline personality disorder; Psychology, medical; Valproic acid

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PHENELZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROATE SEMISODIUM; VALPROIC ACID;

BORDERLINE STATE; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; MEDICAL LITERATURE; MOTOR DYSFUNCTION; PSYCHOSOCIAL CARE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; WEIGHT GAIN;

EID: 77952402780     PISSN: 03911772     EISSN: 18271731     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Klein DF. Psychiatric diagnosis and typology of clinical drug effects. Psychopharmacology 1968;13:359-386
2. Rifkin A, Quitkin F, Carrillo C, Blumberg AG, Klein DF, Oaks G. Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry 1972;27:519-523
3. Kernberg O. Borderline personality organization. J Am Psychoanal Assoc 1967;15:641-685
4. Gunderson JG, Singer MT. Defining borderline patients: An overview. Am J Psychiatry 1975;132:1-10.
5. Barrash J, Kross J, Carey K, Sines L. Discriminating borderline disorder from other personality disorders: Cluster analysis of the Diagnostic Interview for Borderlines. Arch Gen Psychiatry 1983;40:1297-1302 (Pubitemid 14201208)
6. Hoch P, Polatin P. Pseudoneurotic forms of schizophrenia. Psychiatry Q 1949;23:248-276
7. Brinkley JR, Beitman BD, Friedel RO. Low-dose neuroleptic regimens in the treatment of borderline patients. Arch Gen Psychiatry 1979;36:319-326
8. erban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984;141:1455-1458
9. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo. Arch Gen Psychiatry 1986;43:680-686
10. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol and placebo. Arch Gen Psychiatry 1986;43:691-697
11. SCowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranlycopromine. Arch Gen Psychiatry 1988;45:111-119
12. SSoloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50:377-385 (Pubitemid 23143127)
13. SRocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-244
14. SSchulz SC, Camlin KL, Berry S, Friedman L. Risperidone for borderline personality disorder: a double-blind study. 37th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR; 1998.
15. STohen M, Chengappa KN, Suppes T Zarate CA Jr, Calabrese JR, Bowden CL et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69
16. STollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trail of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258
17. SSchulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46:1429-1435
18. SSoloff PH. Is there any drug treatment of chose for the borderline patient? Acta Psychiatr Scand Suppl 1994;379:50-55
19. SBogenschutz MP, George NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:104-109
20. SZanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62:849-854
21. SSchulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomized double-blind placebo controlled study. Br J Psychiatry 2008;193:485-492
22. SZanarini MC, Frankenburg FR. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004;65; 903-907
23. SZanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. 25th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Chicago, IL; 2006.
24. SNickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004;65:1515-1519
25. SCornelius JR, Soloff PH, Perel JM, Ulrich RF. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacology 1991;11:116-120
26. SSalzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15: 23-29
27. SMarkovitz PJ, Calabrese JF, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991;148:1064-1067
28. SLinehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:999-1005.
29. SCoccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior on personality-disordered subjects. Arch Gen Psychiatry 1997;54:116-120
30. SMarkovitz, PJ. Pharmacotherapy of impulsivity, aggression, and related disorders. In: Hollander E, Stein D, editors. Impulsivity and aggression. New York, NY: John Wiley and Sons; 1995. Sp. 263-291
31. SMarkovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995;31:773-777
32. SRinne T, van de Brink W, Wouters L, van Dyck R. SSRI Treatment of borderline personality disorder: a randomized, placebo-controlled trial for female patients. Am J Psychiatry 2002;159:2048-2054
33. SKahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol 1990;10:54-57
34. SDavis GC, Akiska HS. Descriptive, biological, and theoretical aspects of borderline personality disorder. Hosp Community Psychiatry 1986;37:685-692
35. SHollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28:1186-1197
36. SHollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005;162:621-624
37. SFrankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder. J Clin Psychiatry 2002;63:442-446
38. SNickel MK, Nickel C, Kaplan P, Lahmann C, Muhlbacher M, Tritt K et al. Treatment of aggression with topiramate in male borderline personality disorder patients: a double-blind, ptecebo-controlled study. Biol Psychiatry 2005;57:495-499 (Pubitemid 40311984)
39. SPinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51:333-343
40. STritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew Th et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005;19:287-291 (Pubitemid 40694947)
41. SLeiberich P, Nickel MK, Tritt K, Pedrosa Gil F. Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. J Psychopharmacol 2008;22:805-808
42. SReich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 2009;24:270-275
43. SGardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985;142:98-100. (Pubitemid 15189529)
44. SLinehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL Cognitive behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991;48:1060-1064
45. SLinehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993;50:971-974
46. SKoons CR, Robins CJ, Tweed JL, Lynch TR, Gonzalez AM, Morse JQ et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy 2001;32:371-390
47. SLinehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS, Heagerty P et al. Dialectical behavior therapy versus comprehensive validation plus 12-step for the treatment or opioid-dependent women meeting criteria for borderline personality disorder. Drug Alcohol Dependence 2002;67:13-26. (Pubitemid 34615925)
48. SBateman A, Fonagy P. Randomized controlled trial of outpatient mentalization based treatment versus structured clinical management of borderline personality disorder. Am J Psychiatry 2009;166:1355-1364
49. SYoung JE. Cognitive therapy for personality disorder: A schema-focused approach. (Revised ed.). Sarasota, FL: Professional Resources Press; 1999.
50. SGiesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs. transference-focused psychotherapy. Arch of Gen Psych 2006;63:649-658 (Pubitemid 43848296)
51. SBlum N, Pfohl B, St. John D, Monahan P, Black DW. STEPPS: A cognitive behavioral systems-based group treatment for outpaients with borderline personality disorder - a preliminary report. Comprehensive Psychiatry 2002;43:301-310
52. SSimpson EB, Yen S, Costello E, Rosen K, Begin A, Pistoello J et al. Combined dialectical behavior therapy in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:379-385
53. SSoler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005;162:1221-1224
54. SMoen R, Freitag M, Miller M, Lee S, Romine A, Song S, Adityanjee Schulz SC. Extended Release divalproex for borderline personality disorder. Poster session presented at the 20th Annual US Psychiatric and Mental Health Congress; Orlando, R; 2007, October.
55. SSkodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ, Siever LJ. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002;51:936-950
56. SFrankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993;34:402-405
57. SParker GF. Clozapine and borderline personality disorder. Psychiatr Serv 2002;53:348-349